Skip to main content
. 2018 Jan 19;9(12):10536–10548. doi: 10.18632/oncotarget.24276

Figure 3. Lower serum levels of inflammatory cytokines correlate with enhanced survival rates of mCRC patients following bevacizumab treatment.

Figure 3

(A-B). Kaplan-Meier survival curves of above (dotted line) and below (continuous line) median levels of (A.) IL6 (p value=0.053) and (B.) IL8 (p value=0.049) in patient serum prior to commencing bevacizumab treatment versus overall survival in months, n=61.